Cardiology

Dermatology

Endocrinology

Hematology

Lysosomal Disorders 

Neurology

Oncology 

Ophthalmology

Home

News

Media

All Videos

Clinical Trials in Progress

ImmunoLogic

News Network

Partners

CME/CE

Conferences

Subscribe

About Us

Editorial

Contact Us

Terms and Conditions

Do Not Sell My Information

Privacy

CGTLive®

Facebook

LinkedIn

Topics

Lysosomal Disorders

Oncology

1rem

view

The Real-World Impact of CAR T-Cell Therapy in Large B-Cell Lymphoma

Understanding Malignancy Risks With the Use of CAR T-cell Therapies

Videos

Experts explore the clinical significance and practical implications of recent findings regarding a CAR T-cell therapy in real-world settings.

Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, discuss the trajectory and role of of CAR T-cell therapy within the treatment spectrum for LBCL.

The Expanding Utility of CAR T-Cell Therapy in LBCL

Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, share considerations for sequencing CAR T-cell therapies in patients with LBCL, depending on treatments they have already received.

Sequencing With CAR T-Cell Therapy for LBCL

Miguel-Angel Perales, MD, shares insight into the factors he considers when deciding if a patient should receive CAR T-cell therapy in the second line.

CAR T-Cell Therapy as a Second-Line Treatment for LBCL

Miguel-Angel Perales, MD, shares background on the unique design of a real-world analysis of liso-cel in LBCL in which he and his co-investigators prospectively collected retrospective data. 

Caron A. Jacobson, MD, discusses the significance of a real-world follow-up analysis of liso-cel in which safety and efficacy findings in patients with comorbidities and others who were not eligible for clinical trials were consistent with those studies.

Real World Findings for Liso-Cel in LBCL From the Cell Therapy Consortium

Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, review the impact of real-world analysis and how they may shape guidelines and clinical approaches with respect to the use of CAR T-cell therapy in LBCL.In particular, they note how continued research bolsters the safety profile of these agents.

Expert Perspective on Real-World Follow-Up Analyses of Liso-Cel in LBCL

Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, discuss different uses for CAR T-cell therapy, particularly a trial in which a CAR T-Cell therapy is being evaluated in MRD-positive patients treated with chemotherapy. 

Bridging Therapy With CAR T-Cell Therapy in LBCL

Thought leaders discuss patient scenarios and different factors to consider when deciding how to select and utilize bridging therapy in the management of patients with LBCL.

The Impact of Real-World Analyses in the Utilization of CAR T-Cell Therapy in LBCL

The Future of CAR T-Cell Therapy in LBCL

Miguel-Angel Perales, MD, and Caron A. Jacobson, MD, share insights regarding the context and implications of the recent actions by the FDA to add boxed warnings to CAR T-cell therapies.

Back to the Bench: Exploring the Potential of CAR T-Cell Therapy in Oncology

Topic

The News Network video series features a variety of clinicians providing updates on the major data and paradigm-affecting updates from societal meetings and conferences focused on patients with neurologic diseases. It also includes the special RX Reports series on new therapeutics and FDA approvals.

Understanding Malignancy Risks With the Use of CAR T-cell Therapies

EP: 1.The Expanding Utility of CAR T-Cell Therapy in LBCL

EP: 2.Sequencing With CAR T-Cell Therapy for LBCL

EP: 3.CAR T-Cell Therapy as a Second-Line Treatment for LBCL

EP: 4.Understanding Malignancy Risks With the Use of CAR T-cell Therapies

EP: 5.Real World Findings for Liso-Cel in LBCL From the Cell Therapy Consortium

EP: 6.Expert Perspective on Real-World Follow-Up Analyses of Liso-Cel in LBCL

EP: 7.Bridging Therapy With CAR T-Cell Therapy in LBCL

EP: 8.The Impact of Real-World Analyses in the Utilization of CAR T-Cell Therapy in LBCL

EP: 9.The Future of CAR T-Cell Therapy in LBCL

EP: 10.Back to the Bench: Exploring the Potential of CAR T-Cell Therapy in Oncology

Newsletter